The news: Structure Therapeutics’ oral weight loss pill resulted in up to 16% body weight loss, rivaling the results of GLP-1 pills from Novo Nordisk and Eli Lilly.

• Patients in Structure’s 44-week mid-stage study lost from 14.7% to 16.3% of their body weight across 3 different dosing regimens. It plans to start late-stage development this year.
• Structure’s stock rose as much as 7.7% on the news, per Bloomberg.

Why it matters: Structure emerges as another serious contender in the obesity drug market.

• Novo’s Wegovy pill is currently the only GLP-1 weight loss pill on the market (launched in January) although Lilly’s orforglipron could be approved as soon as next month.
• AstraZeneca, Merck, Pfizer, and Roche are among those advancing oral obesity drug treatments.
• Structure is a smaller player, but its strong data and simpler small-molecule GLP-1 make it a credible rival, and a prime target for acquisition.

Demand for no-needle weight loss drugs is already building:

• Wegovy pill prescriptions topped 26,000 within two weeks of launch. By early March, Wegovy pill had more than 600,000 prescriptions, Novo CEO Mike Doudstar told CNBC.
• Nearly half (47%) of overweight Americans not taking a GLP-1 but say they are likely to start one in 2026 would prefer a pill, compared with the 24% who prefer injectables, according to a January Sunlight.com survey.

Implications for weight loss drugmakers: While clinical competitors like Structure Therapeutics advance through late-stage trials, Novo and Lilly are aggressively securing a first-mover advantage in the oral pill segment.

By targeting "needle-averse" customers early, these incumbents are not just capturing market share—they are defining the category’s standard for convenience. For later entrants, simply matching efficacy will be table stakes. Challengers like Structure must deliver differentiated variables such as better tolerability, simplified dose adjustment schedules, or a brand identity that addresses specific patient lifestyle segments, such as new moms.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.